The Need for Cross Border Biotech, Pharma, and Diagnostics Business Development

- China’s economy recovers fast in post COVID-19 era.

- The China pharma market is expected to be the second largest with    further growth of 230% by 2030.

- Funding environment remains positive for biotech in China, China      stood out in the M&A market In-licensing is expected to dominate in    cross border transactions in the next 3-5 years.

- Regulatory reform continues to foster innovation in China, and out      licensing is expected to grow in the next 5 -10 years.

- Experienced cross border business development professionals are    highly needed to facilitate the transactions.